Antioxidant and Antimicrobial Potencies of Chemically-Profiled Essential Oil from Asteriscus graveolens against Clinically-Important Pathogenic Microbial Strains

Mohammed M. Aljeldah

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafar al-Batin 31991, Saudi Arabia; mmaljeldah@uhb.edu.sa

Abstract: Recently, the antimicrobial potential of essential oils extracted from plants has gained extensive research interest, primarily for the development of novel antimicrobial treatments to combat emerging microbial resistance. The current study aims at investigating the antimicrobial activity and chemical composition of essential oil derived from gold coin daisy, which is known as Asteriscus graveolens (EOAG). In this context, a gas chromatography-tandem mass spectrometry (GC-MS) analysis of EOAG was conducted to identify its phytoconstituents. The in vitro antioxidant capacity of EOAG was determined by the use of three tests, namely: 1,1-diphenyl-2-picrylhydrazyl (DPPH), ferric reducing activity power (FRAP), and total antioxidant capacity (TAC). The antimicrobial activity of EOAG against clinically important bacterial (Escherichia coli, ATCC 6633; Bacillus subtilis, DSM 6333; and Pseudomonas aeruginosa, CIP A22) and fungal (Candida albicans, ATCC 10231; Aspergillus niger, MTCC 282; Aspergillus flavus, MTCC 9606; and Fusarium oxysporum, MTCC 9913) strains was assessed. Antimicrobial efficacy was determined on solid (inhibition diameter) and liquid media to calculate the minimum inhibitory concentration (MIC). GC/MS profiling of EOAG revealed that 18 compounds were identified, with a dominance of α-Thujone (17.92%) followed by carvacrol (14.14%), with a total identification of about 99.92%. The antioxidant activity of EOAG was determined to have IC₅₀ values of 34.81 ± 1.12 µg/mL (DPPH), 89.37 ± 5.02 µg/mL (FRAP), and 1048.38 ± 10.23 µg EAA/mg (TAC). The antibacterial activity in a solid medium revealed that the largest diameter was recorded in P. aeruginosa (28.47 ± 1.44 mm) followed by S. aureus (27.41 ± 1.54 mm), and the MIC in S. aureus was 12.18 ± 0.98 µg/mL. For the antifungal activity of EOAG, the largest inhibition diameter was found in F. oxysporum (33.62 ± 2.14 mm) followed by C. albicans (26.41 ± 1.90 mm), and the smallest MIC was found in F. oxysporum (18.29 ± 1.21 µg/mL) followed by C. albicans (19.39 ± 1.0 µg/mL). In conclusion, EOAG can be useful as a natural antimicrobial and antioxidant agent and an alternative to synthetic antibiotics. Hence, they might be utilized to treat a variety of infectious disorders caused by pathogenic microorganisms, particularly those that have gained resistance to standard antibiotics.

Keywords: medicinal plants; clinically important strains; pathogens; bioactive compounds; phytoconstituents

1. Introduction

Historically, medicinal plants have been extensively relied upon for their therapeutic potential, as they have been incorporated into ethnomedical practices dating back hundreds of years [1,2]. In addition to being intensively researched for their usefulness in medicine, plant derivatives have also received a lot of attention for their potential as growth and health promoters. Plant-derived substances have different uses; essential oils, in particular, have drawn special attention because of their widespread use as medicinal and food additives. Preventative and therapeutic medicines are increasingly using phytochemicals, especially those with anticarcinogenic and antibacterial properties [3].

Essential oils (EOs) are sustainably composed of volatile compounds, including terpenes, terpenoids, phenol-derived aromatic components, and aliphatic components with
strong odors, and are generated as secondary metabolites by aromatic plants. EOs possess numerous biological properties, including antibacterial, analgesic, sedative, anti-inflammatory, spasmylostatic, anesthetic, and antioxidant activities [4,5]. To date, these properties have not been altered much, except that more is now known about the modes of action, notably at the antimicrobial level [4].

Antioxidant agents serve a critical role in protecting the human body against several illnesses, including aging, cancer, neurological disease, and arteriosclerosis, as well as other pathological processes [6]. Increasing attention is being paid to plant-derived antioxidants, which might have a significant influence on health protection [7]. Users of food products tend to choose environmentally friendly antioxidants to prevent oxidative destruction from free radicals. Synthetic antioxidants, including tertbutyl hydroquinone, propyl gallate, and butylated hydroxyanisole, are no longer suggested because of their carcinogenic potential [8].

Antimicrobial resistance (AMR) is a phenomenon that happens when bacteria evolve techniques to resist antibiotics intended to kill them, resulting in infections that are difficult to cure and an increased risk of disease transmission [9]. Since it has emerged as one of the most significant challenges affecting the healthcare system in recent decades, scientists have focused their attention more intensely on antibiotic resistance throughout the globe. AMR may emerge as a result of the overuse of medications in human medicine, animal husbandry, and hygiene [7,10,11]. AMR is a major cause for concern today, and if no new medications are produced to combat the underlying pathogens, the death toll might rise to 10 million by 2050, with substantial societal and economic ramifications [12].

Plant species have been extensively studied for their unique pharmacological properties [13], including the Asteraceae family, which is composed of approximately 25,000 species [14]. In this context, Asteriscus graveolens is one of the most popular species of this family that has been reported to possess a pharmacological potency. Hence, it has been widely employed in ethnomedicinal practices to treat various types of pathological conditions such as fever, digestive tract problems, and bronchitis [15]. EOs from Asteriscus graveolens possessed fungicidal properties towards Alternaria sp. and Penicillium expansum [16]. More is known about the EOs of Asteriscus graveolens growing under different climate and edaphic conditions, including anticancer activities, corrosion inhibition, antibacterial and antioxidant properties [17–19].

The chemical composition of EOs from the aerial parts of Asteriscus graveolens was previously profiled and was found to be rich in 6,7-dimethyl-1,5-hydroxy-3,5-octadiene, α-pinene, cedrenol, α-phellandrene, α-himachalene, 1,8-cineole, and T-cadinol [20,21].

The two-fold objectives of this study were: (i) to conduct a GC-MS chemical analysis to identify the phytoconstituents of EOAG and (ii) to investigate its antioxidant, antifungal and antibacterial properties by use of in vitro assays.

2. Materials and Methods

2.1. Plant Material

Leaves of Asteriscus graveolens (Forssk.) Less. were collected in March 2021 from South El-Dahnaa desert, which is located along the road between Damam and Riyadh. The plant was identified by a botanist and was subsequently registered and deposited in the herbarium with the voucher number HR/AG-322. Prior to essential oil (EO) extraction by use of Clevenger apparatus, the leaves were air-dried in the laboratory under shaded conditions for 10 days and subsequently cut into a fine powder using an electric apparatus.

2.2. Extraction of EOAG

Around 200 g of the dry powder of A. graveolens was added to 750 mL of distilled water before being subjected to extraction by the use of a Clevenger-type apparatus at 100 °C for 3 h. The essential oils (EOs) were decanted, dried on Na₂SO₄, and saved far from light at 4 °C until further use.
2.3. Identification of Terpenic Compounds by GC/MS

2.3.1. Gas Chromatography-Flame Ionization Detector (GC-FID)

The separated essential oils (EOAG) were diluted in hexane (10:100), and a sample of 1 µL was taken for gas chromatographic examination. The researchers employed a trace gas chromatograph (GC) (UTRA S/N 20062969, Thermo Fischer, Waltham, MA, USA) with an HP-5MS non-polar fused silica capillary column (60 m, 0.32 mm, film thickness 0.25 mL). Operating conditions: oven temperature program from 50 °C (2 min) to 280 °C at 5 °C/min for 10 min; 2 “split mode” ratio 1:20; nitrogen (N2) carrier gas, flow rate 1 mL/min; injector and detector (flame ionization detector) temperatures were set to 250 °C and 280 °C, respectively.

2.3.2. Gas Chromatography-Mass Spectrometry Analysis (GC-MS)

The EOAG were analyzed using an HP-5MS non-polar fused silica capillary column on a Thermo Fischer capillary gas chromatograph immediately linked to a mass spectrometer system (model GC ULTRA S/N 20062969; Polaris QS/N 210729) (60 m, 0.32 mm, 0.25 mm film thickness). The following was the GC-MS oven temperature working condition: initial temperature 40 °C for 2 min, then 2 °C/min up to 260 °C using isotherm for 10 min; injector temperature 250 °C. The carrier gas was helium, which had a flow rate of 1 mL/min. The essential oils were diluted in hexane at a 10:100 ratio. The injection volume was 1 mL of diluted oil, split injection technique; ionization energy 70 eV, electronic ionization mode; ion source temperature 200 °C, scan mass range of m/z 40–650, and interface line temperature 300 °C. The retention indices (RI) of the components were calculated in comparison to those of a homologous series of n-alkanes (Fluka, Buchs/SG, Switzerland), and their recorded mass spectra were compared to those contained in the spectrometer database (NIST MS Library v. 2.0) and the literature [22].

2.4. Antioxidant Activity of EOAG

The in vitro antioxidant capacity of EOAG was assessed by three methods: DPPH (IC₅₀), TAC, and FRAP (EC₅₀). The antioxidant effectiveness of EOAG was determined by comparison with positive controls, BHT, and quercetin.

2.4.1. DPPH Test

In the present work, 100 µL of EOAG at various concentrations (0.001 to 1 mg/mL) was mixed with 750 µL of DPPH previously prepared in methanol (0.004 %). After incubation at room temperature (RT) for 30 min, values of absorbance were recorded at 517 nm vs. a blank consisting of 750 µL of DPPH (at a final concentration of 0.004% in methanol) and 100 µL of methanol. The antioxidant effectiveness was evaluated by calculating the required concentration for the sample to scavenge 50% of the DPPH free radicals (IC₅₀ in µg/mL). The percentage of inhibition (I%) was calculated based on the following equation:

\[ I\% = \left( \frac{1 - \text{sample}}{\text{control}} \right) \times 100 \]

2.4.2. FRAP Test

The reducing power of EOAG was assessed by adding 1 mL of 0.2 M phosphate buffer (pH = 6.6) and 1 mL of 1% potassium ferricyanide to 0.2 mL of different concentrations of EOAG (0.001 to 1 mg/mL) in methanol (80%). Following incubation at 50 °C for 20 min, 1 mL of TCA (10%), 1 mL of dH₂O, and 0.1% of 0.2 mL of FeCl₃ were added. The absorbance of the reaction media was measured at 700 nm vs. a blank consisting of chemicals and methanol. The results are represented as the 50% effective concentration (EC₅₀), which reflects the concentration of antioxidants needed to give an absorbance of 0.5 nm [23].
2.4.3. TAC Test

Briefly, 2000 µL of H$_2$SO$_4$ solution (0.6 M), 28 mM sodium phosphate buffer, and 4 mM ammonium molybdate were mixed with 50 µL of EOAG (1 mg/mL). The reaction mixture and the blank were placed at 95 °C for 90 min in a water bath. Following cooling, the absorbance was recorded using a UV spectrometer at 695 nm [24,25]. The total antioxidant capacity (TAC) of EOAG was represented as micrograms of ascorbic acid equivalents per milligram of EOs (µg EAA/mg).

2.5. Evaluation of the Antimicrobial Activity of EOAG

The antimicrobial activity of EOAG was assessed using pathogenic strains, including *Escherichia coli*, K12; *Staphylococcus aureus*, ATCC 6633; *Bacillus subtilis*, DSM 6333; and *Pseudomonas aeruginosa*, CIP A22, while fungal activity was tested vs. *Candida albicans*, ATCC 10231; *Aspergillus niger*, MTCC 282; *Aspergillus flavus*, MTCC 9606; and *Fusarium oxysporum*, MTCC 9913. Colonies of the microbial strains were suspended in sterile aqueous NaCl solution (0.9%), and the density of this microbial solution was adjusted to be almost 10$^8$ CFU/mL [26]. The standard antibiotics kanamycin (0.1 mg/mL) and streptomycin (0.1 mg/mL) were utilized as references for comparison to EOAG.

2.5.1. Disc Diffusion Method

The sensitivity of the microbial strains was evaluated using the disc diffusion technique, as described in previous work [27]. First, Petri plates (90 mm) containing Muller Hinton agar, yeast extract–peptone–glycerol, and potato dextrose agar media were inoculated with 1 mL of fresh microbial cultures before standing for 10 min. Following that, 6 mm sterile discs were impregnated with 10 µL of EOAG, and positive controls were placed on the Petri dishes. Finally, the plates were incubated at 37 °C for the bacteria strains, 30 °C for the yeast, and 27 °C for the molds for 24 h and 7 days. Following incubation, the zones around the wells were measured in millimeters.

2.5.2. Determination of Minimum Inhibitory Concentration (MIC)

Briefly, various concentrations of EOAG were directly prepared in agar (0.2%). The dilutions of different microbial strains were performed as described in earlier work [27], by pouring 50 µL of inoculum into 96-well plates prior to incubation for 20 h at 37 °C. Next, the microbial growth was visualized by adding 10 µL of 2,3,5-triphenyltetrazolium chloride (TTC) (1%) to each well. Notably, the wells containing bacterial growth became pink due to the activity of the dehydrogenases, while the wells without bacterial growth remained colorless after 2 h of incubation. Therefore, the MIC was determined to be the lowest concentration showing no pink color [26].

2.6. Statistical Analysis

The findings presented in this research work are expressed as means with standard deviations of triplicate tests. The Shapiro–Wilks test was used to check normality, and Levene’s test was used to verify the homogeneity of variance. Tukey’s t test was employed as a post-hoc test for multiple comparisons. Statistical significance was considered at the cutoff of $p \leq 0.05$.

3. Results and Discussion

3.1. GC-MS Profiling of EOAG

The yield of EOAG obtained by the hydrodistillation of aerial parts of *A. graveolens* was 0.61%, which is higher than that of *A. graveolens* subsp. odorus growing elsewhere with a calculated value of 0.50% [25]. Moreover, the obtained EO yield is comparable to that reported by other EO-producing plants that have been widely exploited for EO production [26,27]. The analysis of EOAG by GC/MS revealed eighteen compounds constituting 99.92% of the total oil mass (Figure 1 and Table 1). EOAG is mainly composed of α-thujone (17.92%), carvacrol (14.14%), p-cineole (13.83%) and camphor (12.71 %) (Table 1.
and Figure 2). Oxygenated monoterpenes (66.07%), monoterpene hydrocarbons (19.59%), and sesquiterpene hydrocarbons (10.22%) are predominant in EOAG (Table 1). These results are in accordance with the literature reporting that A. graveolens subsp. odorus is higher in oxygenated sesquiterpenes (56.05%) and oxygenated monoterpenes (53.9%) [25,28]. The results of EOAG chemical composition presented here agree with those reported by Cristofari and co-authors who showed that the aerial parts of A. graveolens were characterized by a high content of oxygenated sesquiterpenes with 6-oxo- and 6-hydroxycyclonerolidol as predominant components [29]. The difference in the chemical composition of EOs from A. graveolens growing in different geographical areas can be due to differences in the environmental and edaphic conditions predominant these areas, resulting in metabolic changes. In addition, the method employed in the extraction with solvents can also be responsible for differences [30,31].

![Chromatographic profile of EOAG by GC/MS.](image)

**Table 1.** Volatile compounds of EO identified by GC/MS.

| RT   | Compound     | Retention Index | Chemical Class | Area (%) |
|------|--------------|-----------------|----------------|----------|
| 1    | α-Pinene     | 938             | MO.H           | 5.10     |
| 2    | Camphene     | 949             | MO.H           | 2.91     |
| 3    | β-Pinene     | 974             | MO.H           | 1.58     |
| 4    | Myrcene      | 988             | MO.H           | 1.16     |
| 5    | o-Cymene     | 1022            | MO.H           | 5.50     |
| 6    | Limonene     | 1028            | MO.H           | 1.16     |
| 7    | p-Cineole    | 1039            | MO.O           | 13.83    |
| 8    | γ-Terpinene  | 1058            | MO.H           | 1.98     |
Table 1. Cont.

| RT  | Compound          | Retention Index | Chemical Class | Area (%) |
|-----|-------------------|-----------------|----------------|----------|
| 9   | Isothujone        | 1002            | MO.O           | 3.98     |
| 10  | α-Thujone         | 1102            | MO.O           | 17.92    |
| 11  | Camphor           | 1141            | MO.O           | 12.71    |
| 12  | Borneol           | 1168            | MO.O           | 1.23     |
| 13  | Carvacrol         | 1297            | MO.O           | 14.14    |
| 14  | Thymol acetate    | 1357            | MO.O           | 2.26     |
| 15  | Caryophyllene     | 1404            | ST.H           | 6.71     |
| 16  | α-Humulene        | 1459            | ST.H           | 3.51     |
| 17  | Eugenol acetate   | 1525            | O              | 0.61     |
| 18  | Pogostol          | 1651            | ST.O           | 3.43     |

Chemical Class

- Monterpene oxygenated (MO.O) 66.07%
- Monoterpene hydrocarbons (MO.H) 19.59%
- Other (O) 0.61%
- Sesquiterpene oxygenated (ST.O) 3.43%
- Sesquiterpene hydrocarbons (ST.H) 10.22%
- Total 99.92%

RT; Retention time; MO.O: Monterpene oxygenated; MO.H: Monoterpene hydrocarbons; O: Other; ST.O: Sesquiterpene oxygenated; ST.H: Sesquiterpene hydrocarbons.

Figure 2. Molecular structures of the major compounds in EOAG.

3.2. In Vitro Antioxidant Activity of EOAG

The antioxidant power, which was assessed by use of the DPPH method, revealed that EOAG exhibited potent antioxidant power in a dose–response association (Figure 3).

Notably, inhibitions of free radicals on the order of 19.50 ± 0.71 %, 69.50 ± 0.70 %, and 89.17 ± 0.61 % were recorded for concentrations of 3 µg/mL, 60 µg/mL, and 100 µg/mL, respectively.
3.2. In Vitro Antioxidant Activity of EOAG

The antioxidant power, which was assessed by use of the DPPH method, revealed that EOAG exhibited potent antioxidant power in a dose–response association (Figure 3). Notably, inhibitions of free radicals on the order of 19.50 ± 0.71 %, 69.50 ± 0.70 %, and 89.17 ± 0.61 % were recorded for concentrations of 3 µg/mL, 60 µg/mL, and 100 µg/mL, respectively. The antioxidant efficiency of EOAG by DPPH is given in IC$_{50}$, which was determined to be 34.81 ± 1.12 µg/mL. This value can be considered important when compared to those obtained with BHT and quercetin, which were used as positive controls and exhibited values of 19.68 ± 0.95 µg/mL and 24.57 ± 0.81 µg/mL, respectively (Figure 3). The antioxidant power of EOAG remains important when compared to that investigated by Alilou and co-authors [25], reporting an IC$_{50}$ value of A. graveolens on the order of 249 µg/mL. The antioxidant potency of EOAG, as assessed by the DPPH assay, with an IC$_{50}$ value of 34.81 ± 1.12 µg/mL is better than that found by Aouissi and co-authors who reported that the IC$_{50}$ value of A. graveolens indigenous to Algeria was 420.16 mg/mL [18]. This difference can be due to differences in environmental and edaphic influences the plant growth, resulting in phytochemical composition changes, which in turn affect antioxidant power [31]. The results of the reducing power assay showed that EOAG recorded good antioxidant activity with an average EC$_{50}$ value of EOAG of 89.37 ± 5.02 µg/mL, which is considered important when compared to standards BHT and quercetin, which registered EC$_{50}$ values of 64.29 ± 4.15 µg/mL and 49.83 ± 2.69 µg/mL, respectively (Figure 3).

![Figure 3](image-url)

Figure 3. The antioxidant power of EOAG by the FRAP (EC$_{50}$) and by DPPH (IC$_{50}$) assays.
The total antioxidant capacity (TAC) determined by ammonium molybdate method revealed that the antioxidant capacity of EOAG was on the order of 1048.38 ± 10.23 µg EAA/mg, while BHT and quercetin, which were used as chemical references recorded 987.46 ± 7.47 µg EAA/mg and 891.73 ± 8.22 µg/mg, respectively (Figure 4). These results are in accordance with those reported by Aouissi and co-authors, who determined the total antioxidant capacity of EOs of A. graveolens from Algeria was 0.28 AAEC/mg [18]. Previous literature reported that terpenic compounds, i.e., carvacrol and α-thujone, decreased the degree of peroxidation of the phospholipids present in liposomes in the presence of iron (III), which might explain the antioxidant power of EOAG in this study [32]. Scientific studies have shown that major compounds in EOs may be the potent agents responsible for the antioxidant power without excluding compounds detected in minute amounts, which may also react synergistically [33].

3.3. Evaluation of Antibacterial Activity of EOAG

The antibacterial potency of EOAG was determined by measuring the inhibition zone diameters and by determining the minimum inhibitory concentrations (MICs). The results showed that EOAG exhibited potent antibacterial effects vs. all tested bacteria (Table 2 and Figure 5). Notably, the largest inhibition diameter of EOAG was recorded for P. aeruginosa, which scored 28.47 ± 1.44 mm, followed by S. aureus with a calculated value of 27.41 ± 1.54 mm, whereas almost all bacteria showed resistance against kanamycin and streptomycin except for S. aureus and E. coli (Table 2 and Figure 5). Similarly, the MIC results showed that EOAG strongly inhibited the bacterial pathogenic strains used for testing, recording MICs values ranging from 12.18 ± 0.98 to 14.65 ± 1.28 µg/mL (Table 2).

Table 2. Antibacterial power of EOAG as assessed by use of inhibition zone diameters and MIC assays.

|       | S. aureus | E. coli | B. subtilis | P. aeruginosa |
|-------|-----------|---------|-------------|--------------|
| **EOAG** |           |         |             |              |
| Inhibition diameter (mm) | 27.41 ± 1.54<sup>a</sup> | 19.68 ± 1.25<sup>b</sup> | 17.48 ± 1.75<sup>b</sup> | 28.47 ± 1.44<sup>a</sup> |
| MIC (µg/mL) | 12.18 ± 0.98<sup>b</sup> | 14.57 ± 0.87<sup>b</sup> | 22.48 ± 0.69<sup>a</sup> | 14.65 ± 1.28<sup>a</sup> |
| **Stp** |           |         |             |              |
| Inhibition diameter (mm) | 10.73 ± 0.45<sup>a</sup> | 0<sup>b</sup> | 0<sup>b</sup> | 0<sup>b</sup> |
| MIC (µg/mL) | 15.83 ± 0.20<sup>a</sup> | 0<sup>b</sup> | 0<sup>b</sup> | 0<sup>b</sup> |
| **Kan** |           |         |             |              |
| Inhibition diameter (mm) | 0<sup>b</sup> | 17.24 ± 1.34<sup>a</sup> | 0<sup>b</sup> | 0<sup>b</sup> |
| MIC (µg/mL) | 0<sup>b</sup> | 13.47 ± 0.92<sup>a</sup> | 0<sup>b</sup> | 0<sup>b</sup> |

Row values with different letters differed significantly (one-way ANOVA; Tukey test, p < 0.05). MIC: minimum inhibitory concentration; *Staphylococcus aureus* ATCC 6633; *Escherichia coli* K12; *Bacillus subtilis* DSM 6333; *Pseudomonas aeruginosa* CIP A22; Stp: Streptomycin; Kan: Kanamycin.
The antibacterial capabilities and features of EOs can be well-recognized for their ability to combat hospital-acquired illnesses and pandemic multi-resistant bacteria [26,27,35]. The antibacterial capabilities and features of EOs can be easily cross bacterial cell walls and the cytoplasmic membrane, resulting in polysaccharide and phospholipid permeability disorders, which may lead to immediate bacterial death [40]. The molecular interaction of EO components with the bacterial membrane results in serious lesions, which might explain their antibacterial activity. It is also possible that compounds in EOs react in synergy or individually to have antibacterial effects [27].

3.4. Evaluation of Antifungal Activity of EOAG

Scientific studies have shown that the EOs with MICs ranging from 19 to 100 µg/mL are considered potent antibacterial agents [34]. It is thus fitting that our results are in agreement with this literature since the MIC values obtained with EOAG ranged from 12.18 ± 0.98 to 14.65 ± 1.28 µg/mL. The antibacterial results presented here agree with those found by Aouissi and co-authors who showed important antibacterial activity of Eos of A. graveolens from Algeria against Escherichia coli, Klebsiella pneumonia, Salmonella typhi, Pseudomonas aeruginosa, Bacillus cereus, and Enterococcus faecalis [18]. EOs are now well-recognized for their ability to combat hospital-acquired illnesses and pandemic multi-resistant bacteria [26,27,35]. The antibacterial capabilities and features of EOs can be explained by their lipophilic nature, which allows them to easily permeate the bacterial cell and eventually cause the bacterium’s death. Terpenes and hydrocarbons in EOs have been shown to preferentially react with the biological membranes of bacteria, resulting in membrane permeability disturbance, which ultimately leads to bacterial mortality [35,36]. More detailed scientific investigations on the mechanism of action of EOs containing hydrocarbon terpenes can help us better understand how they affect bacteria [37].

Figure 5. Photographs showing inhibition zones against bacteria. (a): negative control; (b): B. subtilis; (c): E.coli; (d): positive control.
Remarkably, the largest inhibition zone diameters were recorded in *F. oxysporum*, with a calculated value of $33.62 \pm 2.14$ mm, followed by *C. albicans*, with a noticed value of $26.41 \pm 1.90$ mm. The results noted the antifungal resistance of *C. albicans* and *A. flavus* to fluconazole, which was used as a drug reference (Table 3). Similarly, the MIC results showed that EOAG strongly inhibited the fungal pathogenic strains used for testing, recording MICs values ranging from $18.29 \pm 1.21$ to $24.50 \pm 1.30 \mu g/mL$ (Table 3).

### Table 3. Antifungal power of EOAG as assessed by use of inhibition zone diameters and MIC assays.

|       | *C. albicans* | *A. niger* | *A. flavus* | *F. oxysporum* |
|-------|---------------|------------|-------------|----------------|
| **EOAG** |               |            |             |                |
| Inhibition diameter (mm) | $26.41 \pm 1.90^a$ | $17.01 \pm 1.08^b$ | $16.76 \pm 1.02^b$ | $33.62 \pm 2.14^c$ |
| MIC (µg/mL) | $19.39 \pm 1.0^a$ | $24.50 \pm 1.30^b$ | $23.74 \pm 1.81^b$ | $18.29 \pm 1.21^a$ |
| **Flu** |               |            |             |                |
| Inhibition diameter | $0^a$ | $11.41 \pm 1.31^b$ | $0^a$ | $16.18 \pm 2.43^c$ |
| MIC (µg/mL) | $0^a$ | $10.27 \pm 0.84^b$ | $0^a$ | $33.12 \pm 1.38^c$ |

Row values with different letters differed significantly (one-way ANOVA; Tukey test, $p < 0.05$). MIC: minimum inhibitory concentration; Staphylococcus aureus ATCC 6533; Escherichia coli K12; Bacillus subtilis DSM 6333; Pseudo-monas aeruginosa CIP A22; Strep: Streptomycin; Kan: Kanamycin; R: Resistant; C.A: Candida albicans ATCC 10231; Aspergillus niger MTCC 282; Aspergillus flavus MTCC 9606; Fusarium oxysporum MTCC 9913; Flu: Fluconazole.

Fungal infections are common in hospitalized patients around the world with several risk factors associated with a shortage of diagnoses [41]. Many epidemiological data on fungal infections reported that the fungal strains instigated in the present work are involved in a wide range of illnesses. Notably, Candida species have been shown to be responsible for nosocomial invasive fungal infections in hospitalized patients and are responsible for 8 to 10% of all nosocomial infections [35]. According to previous reports, invasive candidiasis is commonly associated with high fatality rates, and controlling these infections can be difficult because some antifungal treatments are no longer effective against resistant forms [27]. It is thus fitting that looking for an alternative treatment to control such infections is more warranted to control AMR. Based on their results in combating pathogens, EOs can be investigated as an alternative treatment to control fungal infections [42]. In the present work, the major components in EOAG might act individually or synergistically in association with those present in minute quantities to inhibit the mycelial growth of fungal strains. The antifungal activity investigated in the present work can be attributed to $\alpha$-thujone and carvacrol, which were revealed by GCMS in higher amounts in EOAG (Table 1) [31,35]. The antifungal results presented here are consistent with those found by Znini and co-authors who reported that EOs from *A. graveolens* possessed antifungal potency against postharvest phytopathogenic fungi in apples, namely, *Alternaria* sp. from the direct contact assay and *P. expansum* from the vapor assay tests [16]. Moreover, Aouissi and co-authors showed important antifungal activity of EOs of *A. graveolens* growing in Algeria against *Fusarium* *f. sp., Fusarium* *f. sp. lycopersici, Fusarium graminearum,* and *Fusarium culmorum* [18]. The toxicity of EOs against fungi might be attributed to EO terpenes and phenolic compounds, which are known to disrupt cell membranes, causing cellular material leakage and eventually causing microorganism death by inhibiting mitochondrial ATPase and the electron transport chain [35,43].

### 4. Conclusions

The present work investigates the chemical composition of EOs from the aerial parts of *Asteriscus graveolens* and their antioxidant, antibacterial, and antifungal properties. EOs were shown to have reasonable antioxidant and antimicrobial capabilities, which might be ascribed to the high concentrations of certain bioactive compounds such as $\alpha$-thujone and carvacrol. The findings of the current research highlighted the advantages of EOAG as an effective eco-friendly agent with antioxidant and antimicrobial activities. Further research
is thus required to assess the safety of these EOs as well as their non-target toxicity in both animals and humans.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All data reported here are available from the authors upon request.

**Conflicts of Interest:** The author declares no conflict of interest.

**Sample Availability:** Samples of EOAG are available upon request from the author.

**References**

1. Bellakhdar, J. *The Traditional Moroccan Pharmacopoeia: Ancient Arabic Medicine and Popular Knowledge*; Ibis Press: Paris, France, 1997.
2. Bourhim, M.; Messaoudi, M.; Bakrim, H.; Mothana, R.A.; Sddiqii, N.A.; Almarfadi, O.M.; El Mizibri, M.; Gmouh, S.; Laglaoui, A.; Benbacer, L. Citrusus colocynthis (L.) Schrad: Chemical Characterization, Scavenging and Cytotoxic Activities. *Open Chem.* 2020, 18, 986–994. [CrossRef]  
3. Lardry, J.-M.; Haberkorn, V. L’aromathérapie et Les Huiles Essentielles. *Kinésithérapie La Rev.* 2007, 7, 14–17. [CrossRef]  
4. Bakkali, F.; Averbeck, S.; Averbeck, D.; Idaomar, M. Biological Effects of Essential Oils—A Review. *Food Chem. Toxicol.* 2008, 46, 446–475. [CrossRef] [PubMed]  
5. Janssen, A.M.; Scheffer, J.J.C.; Svendsen, A.B. Antimicrobial Activity of Essential Oils: A 1976-1986 Literature Review. *Aspects Test Methods. Planta Med.* 1987, 53, 395–398.  
6. Erdemoglu, N.; Turan, N.N.; Cakoc, I.; Sener, B.; Aydon, A. Antioxidant Activities of Some Lamiaceae Plant Extracts. Phytotherapy Research: An International. *J. Devoted Pharmacol. Toxicol. Eval. Nat. Prod. Deriv.* 2006, 20, 9–13.  
7. Pieroni, A.; Janiak, V.; Dürr, C.M.; Lüdeke, S.; Trachsel, E.; Heinrich, M. In Vitro Antioxidant Activity of Non-Cultivated Vegetables of Ethnic Albanians in Southern Italy. *Phytother. Res. Int. J. Devoted Pharmacol. Toxicol. Eval. Nat. Prod. Deriv.* 2002, 16, 467–473.  
8. Ames, B.N. Dietary Carcinogens and Anticarcinogens: Oxygen Radicals and Degenerative Diseases. *Science* 1983, 221, 1256–1264. [CrossRef]  
9. Vickers, N.J. Animal Communication: When I’m Calling You, Will You Answer Too? *Curr. Biol.* 2017, 27, R713–R715. [CrossRef]  
10. Calo, J.R.; Crandall, P.G.; O’Bryan, C.A.; Ricke, S.C. Essential Oils as Antimicrobials in Food Systems—A Review. *Food Control* 2015, 54, 111–119. [CrossRef]  
11. Sumathi, T.; Sri lakshmi, A.; Kotakadi, V.S.; Saigopal, D.V.R. Role_of_Fungal_Enzymes_in_Polymer_degradation_n: A Mini review. *Res. J. Pharm. Biol. Chem. Sci.* 2014, 5, 1694–1711.  
12. O’Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations; Wellcome Collection: London, UK, 2016. Available online: https://wellcomecollection.org/works/thwssub (accessed on 20 April 2022).  
13. Maksimovic, Z.; Marenčić, D.; Kovačević, N. Polyphenol Contents and Antioxidant Activity of Maydis Stigma Extracts. *Bioreour. Technol.* 2005, 96, 873–877. [CrossRef]  
14. Alvarenga, S.A.V.; Ferreira, M.J.P.; Emerenciano, V.; Cabrol-Bass, D. Chemosystematic Studies of Natural Compounds Isolated from Asteraceae: Characterization of Tribes by Principal Component Analysis. *Chemom. Intell. Lab. Syst.* 2001, 56, 27–37. [CrossRef]  
15. Ramdane, F.; Essid, R.; Mkadmini, K.; Hammami, M.; Fares, N.; Mahammed, M.H.; El Ouassid, D.; Tabbene, O.; Limam, H.; Hadji, M.D.O. Phytochemical Composition and Biological Activities of Asteriscus Graveolens (Forssk) Extracts. *Process Biochem.* 2017, 56, 186–192. [CrossRef]  
16. Znini, M.; Cristofari, G.; Majidi, L.; Mazouz, H.; Tomi, P.; Paolini, J.; Costa, J. Antifungal Activity of Essential Oil from Asteriscus Graveolens against Postharvest Phytopathogenic Fungi in Apples. *Nat. Prod. Commun.* 2011, 6, 1934578X1100601147. [CrossRef]  
17. Achoub, H.; Mencherini, T.; Esposito, T.; Luca, R.; Aquino, R.; Gazzarro, P.; Zaiter, L.; Benayache, F.; Benayache, S. New sesquiterpenes from Asteriscus graveolens. *Nat. Prod. Res.* 2021, 35, 2190–2198. [CrossRef]  
18. Aouissi, H.; Gourine, N.; Wang, H.; Chen, X.; Bondar, I.; Boujdeniba, M.; Yousfi, M. Chemical Composition, Antioxidative, Antimicrobial and Anti-Cancer Activities of Asteriscus graveolens (Forssk) Essential Oil. *Orient. Pharm. Exp. Med.* 2018, 18, 217–223. [CrossRef]  
19. Chaib, F.; Allali, H.; Benali, O.; Flamini, G. Corrosion Inhibition Effects of the Essential Oils of Two Asteraceae Plants from South Algeria. *Inter. J. Chem. Biochem. Sci.* 2018, 12, 138–145.  
20. Cheriti, A.; Saad, A.; Belboukhari, N.; Ghezali, S. The Essential Oil Composition of Bubonium Graveolens (Forssk.) Maire from the Algerian Sahara. *Flavour Fragr. J.* 2007, 22, 286–288. [CrossRef]  
21. Fahmy, H.S. Chemical Composition and Antimicrobial Activity of the Volatile Oil of Nauplius Graveolens (Forssk.). *Less. J. Environ. Sci.* 2003, 26, 307–317.  
22. Adams, R.P. Identification of Essential Oil Components by Gas Chromatography/Mass Spectrometry, 4th ed.; Allured Publishing Corporation: Carol Stream, IL, USA, 2007; ISBN 978-1-932(33-11-4).
